FDA Breakthrough: Promogran Prisma™ Expands the Limits of Wound Care
The wound care industry just hit a significant milestone. As of March 13, 2026, the FDA has cleared Promogran Prisma™ Collagen Matrix for integrated use with Negative Pressure Wound Therapy (NPWT).
As researchers closely following these developments, we see this as a pivotal shift toward more versatile, “all-in-one” clinical solutions.
The Technical Edge
The power of Promogran Prisma™ lies in its 3-in-1 composite structure:
55% Collagen: Creates the essential scaffold for new tissue growth.
44% ORC: Inactivates harmful proteases (MMPs) that stall healing.
1% Silver-ORC: Provides a sustained antimicrobial barrier against infection.
Why It’s a Game Changer
Seamless Integration: It is now officially validated for use with systems like ActiV.A.C.™, allowing clinicians to combine biological healing with mechanical therapy.
Micro-Conformity: Upon contact with exudate, the matrix transforms into a biodegradable gel, ensuring 100% contact with irregular wound beds.
Inventory Efficiency: One product now serves two major treatment modalities, simplifying the workflow for complex diabetic and venous ulcers.
The Bottom Line
This clearance removes the “either/or” barrier between biological dressings and NPWT. It’s a sophisticated, streamlined approach to restarting the healing clock on the most stubborn chronic wounds.
Source: FDA K251999